Detalles de la búsqueda
1.
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Lancet Oncol
; 25(2): 212-224, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38134948
2.
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 401(10389): 1655-1668, 2023 05 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37068504
3.
Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies.
Jpn J Clin Oncol
; 54(4): 434-443, 2024 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38231777
4.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
N Engl J Med
; 382(25): 2419-2430, 2020 06 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-32469182
5.
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
N Engl J Med
; 383(13): 1207-1217, 2020 09 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-32955176
6.
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).
BMC Cancer
; 23(1): 180, 2023 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36814222
7.
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.
Gastric Cancer
; 25(1): 197-206, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34468869
8.
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lancet Oncol
; 22(12): 1740-1751, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34793719
9.
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Invest New Drugs
; 39(6): 1587-1597, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34180037
10.
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.
Gastric Cancer
; 24(6): 1330-1340, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34363528
11.
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.
Future Oncol
; 17(22): 2847-2855, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33975465
12.
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.
Future Oncol
; 17(5): 491-501, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33167735
13.
S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 21(8): 1045-1056, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32682457
14.
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Lancet Oncol
; 21(10): 1353-1365, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32919526
15.
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Lancet Oncol
; 21(8): 1066-1076, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32653053
16.
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts.
Cancer Sci
; 111(2): 536-547, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31778267
17.
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
Cancer Sci
; 111(2): 513-527, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31789476
18.
Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study.
Br J Cancer
; 121(4): 332-339, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31312030
19.
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Lancet
; 392(10142): 123-133, 2018 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29880231
20.
A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors.
Oncologist
; 24(8): 1037-e636, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31164456